Zanidatamab
- Generic Name
- Zanidatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169946-15-8
- Unique Ingredient Identifier
- Z20OC92TDI
- Background
According to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to significant anti-tumor activity in preclinical models of breast and gastric cancers."
- Associated Conditions
- -
- Associated Therapies
- -
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase
FDA approved AstraZeneca's Voydeya for a rare blood disorder. Merck's KRAS inhibitor, MK-1084, enters phase III for NSCLC. Jazz Pharmaceuticals filed for zanidatamab approval for HER2-positive BTC. AstraZeneca and Daiichi Sankyo's ADC, Dato-DXd, under FDA review for breast cancer. Merck's R-DXd in phase II/III for ovarian cancer.
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
Jazz Pharmaceuticals completes BLA submission for zanidatamab, a HER2-targeted bispecific antibody, seeking accelerated approval for treatment of previously-treated HER2-positive metastatic biliary tract cancer. If approved, zanidatamab would be the first HER2-targeted treatment for this indication in the U.S. The BLA includes data from the Phase 2b HERIZON-BTC-01 trial showing a confirmed objective response rate of 41.3% in HER2-positive BTC patients, with a manageable safety profile.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
The article highlights 12 undervalued biotech stocks favored by hedge funds, focusing on companies like MEI Pharma, Ocuphire Pharma, and Voyager Therapeutics. It discusses the biotech industry's growth, driven by innovation, M&A activity, and FDA approvals, with a positive outlook for 2024 despite challenges like drug pricing and regulatory scrutiny.
Zymeworks Outlines Strategic Priorities and Outlook for 2024-2025
Zymeworks Inc. updates on 2024-2025 strategic priorities, including zanidatamab's Phase 3 trial data expected in 2024, regulatory reviews, and IND applications for new candidates. With $455M cash resources, the company plans to extend its R&D efforts into 2027, focusing on ADCs and multispecific antibody therapeutics.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath